Enzo Biochem (NYSE:ENZ) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a research report released on Wednesday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Trading Up 2.7 %

Shares of ENZ stock opened at $1.16 on Wednesday. Enzo Biochem has a one year low of $0.99 and a one year high of $1.50. The firm has a 50-day moving average of $1.13 and a 200-day moving average of $1.11.

Enzo Biochem Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 15th will be given a $0.10 dividend. The ex-dividend date is Friday, November 15th.

Institutional Investors Weigh In On Enzo Biochem

An institutional investor recently raised its position in Enzo Biochem stock. XTX Topco Ltd boosted its stake in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 94.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,262 shares of the medical research company’s stock after buying an additional 13,735 shares during the quarter. XTX Topco Ltd owned approximately 0.05% of Enzo Biochem worth $31,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.